[
  {
    "ts": null,
    "headline": "AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating",
    "summary": "AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the companyâs future looks bright.",
    "url": "https://finnhub.io/api/news?id=b0bffa5a9ae5c47a255e185aa2cf65897e628d26de0c5f6cfe30db3a2a88b556",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737639382,
      "headline": "AstraZeneca's Growth Potential: 6 Reasons For A Buy Rating",
      "id": 132449871,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/107429764/image_107429764.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the companyâs future looks bright.",
      "url": "https://finnhub.io/api/news?id=b0bffa5a9ae5c47a255e185aa2cf65897e628d26de0c5f6cfe30db3a2a88b556"
    }
  },
  {
    "ts": null,
    "headline": "Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement",
    "summary": "INDIANAPOLIS, Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a...",
    "url": "https://finnhub.io/api/news?id=3c7cea1c1cef589c49402f3d7d74d38f6b3e8ea11281e302ac925c9a4146027d",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737626468,
      "headline": "Lilly confirms date and conference call for fourth-quarter 2024 financial results and 2025 financial guidance announcement",
      "id": 132448899,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS, Jan. 23, 2025 /PRNewswire/ -- Eli Lilly and Company will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb. 6, 2025. Lilly will also conduct a...",
      "url": "https://finnhub.io/api/news?id=3c7cea1c1cef589c49402f3d7d74d38f6b3e8ea11281e302ac925c9a4146027d"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: Investors Meeting Reality Of The Obesity Market",
    "summary": "Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.",
    "url": "https://finnhub.io/api/news?id=d36aded5203105df503d71a1d2d3006d6a7ce702ed2960f15d68ee186d862f6f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737623700,
      "headline": "Viking Therapeutics: Investors Meeting Reality Of The Obesity Market",
      "id": 132448770,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190382211/image_2190382211.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.",
      "url": "https://finnhub.io/api/news?id=d36aded5203105df503d71a1d2d3006d6a7ce702ed2960f15d68ee186d862f6f"
    }
  },
  {
    "ts": null,
    "headline": "This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.",
    "summary": "This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.",
    "url": "https://finnhub.io/api/news?id=2f6820a2147d9f0ededc7d79480289e92373f4bd56224d7b19884db488c34ec8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1737617880,
      "headline": "This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.",
      "id": 132458820,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "This Weight-Loss Drug Stock Could Gain 200%. The Case for It to Challenge Novo, Lilly.",
      "url": "https://finnhub.io/api/news?id=2f6820a2147d9f0ededc7d79480289e92373f4bd56224d7b19884db488c34ec8"
    }
  }
]